{"id":"https://openalex.org/W3191106360","doi":"https://doi.org/10.1002/cpdd.990","title":"Apixaban Single\u2010Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration","display_name":"Apixaban Single\u2010Dose Pharmacokinetics, Bioavailability, Renal Clearance, and Pharmacodynamics Following Intravenous and Oral Administration","publication_year":2021,"publication_date":"2021-08-02","ids":{"openalex":"https://openalex.org/W3191106360","doi":"https://doi.org/10.1002/cpdd.990","mag":"3191106360","pmid":"https://pubmed.ncbi.nlm.nih.gov/34342172"},"language":"en","primary_location":{"id":"doi:10.1002/cpdd.990","doi":"https://doi.org/10.1002/cpdd.990","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cpdd.990","pdf_url":null,"source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103820467","display_name":"Charles E. Frost","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles Frost","raw_affiliation_strings":["Clinical Pharmacology and Pharmacometrics, Bristol Myers Squibb, Princeton, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology and Pharmacometrics, Bristol Myers Squibb, Princeton, New Jersey, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060181316","display_name":"Samira J. Merali","orcid":"https://orcid.org/0000-0001-6659-3687","observed_orcids":["https://orcid.org/0000-0001-6659-3687"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Samira Garonzik","raw_affiliation_strings":["Clinical Pharmacology and Pharmacometrics, Bristol Myers Squibb, Princeton, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology and Pharmacometrics, Bristol Myers Squibb, Princeton, New Jersey, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049683780","display_name":"Andrew Shenker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Shenker","raw_affiliation_strings":["Clinical Pharmacology and Pharmacometrics, Bristol Myers Squibb, Princeton, New Jersey, USA","At time of research"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology and Pharmacometrics, Bristol Myers Squibb, Princeton, New Jersey, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"At time of research","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110207659","display_name":"Yu Chen Barrett","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yu Chen Barrett","raw_affiliation_strings":["Clinical Pharmacology and Pharmacometrics, Bristol Myers Squibb, Princeton, New Jersey, USA","At time of research"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology and Pharmacometrics, Bristol Myers Squibb, Princeton, New Jersey, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"At time of research","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5087648612","display_name":"Frank P. LaCreta","orcid":"https://orcid.org/0000-0001-8266-5927","observed_orcids":["https://orcid.org/0000-0001-8266-5927"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Frank LaCreta","raw_affiliation_strings":["Clinical Pharmacology and Pharmacometrics, Bristol Myers Squibb, Princeton, New Jersey, USA","At time of research"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology and Pharmacometrics, Bristol Myers Squibb, Princeton, New Jersey, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"At time of research","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5060181316"],"corresponding_institution_ids":["https://openalex.org/I4210091812"],"apc_list":{"value":3300,"currency":"USD","value_usd":3300},"apc_paid":null,"fwci":1.7765,"has_fulltext":false,"cited_by_count":17,"citation_normalized_percentile":{"value":0.84733024,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"10","issue":"9","first_page":"974","last_page":"984"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10881","display_name":"Blood Coagulation and Thrombosis Mechanisms","score":0.6801999807357788,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10881","display_name":"Blood Coagulation and Thrombosis Mechanisms","score":0.6801999807357788,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10065","display_name":"Atrial Fibrillation Management and Outcomes","score":0.12319999933242798,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.07540000230073929,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/apixaban","display_name":"apixaban","score":1.0},{"id":"https://openalex.org/keywords/factor-xa-inhibitors","display_name":"factor Xa inhibitors","score":0.796999990940094},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9319999814033508},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.8230000138282776},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.9769999980926514},{"id":"https://openalex.org/keywords/renal-clearance","display_name":"renal clearance","score":0.9700000286102295},{"id":"https://openalex.org/keywords/plasma-clearance","display_name":"plasma clearance","score":0.7760000228881836},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.6990000009536743},{"id":"https://openalex.org/keywords/anti-xa-activity","display_name":"anti-Xa activity","score":0.7749999761581421},{"id":"https://openalex.org/keywords/prothrombin-time","display_name":"prothrombin time","score":0.8420000076293945},{"id":"https://openalex.org/keywords/international-normalized-ratio","display_name":"international normalized ratio","score":0.9599999785423279},{"id":"https://openalex.org/keywords/intravenous-administration","display_name":"intravenous administration","score":0.7459999918937683},{"id":"https://openalex.org/keywords/oral-administration","display_name":"oral administration","score":0.9390000104904175},{"id":"https://openalex.org/keywords/bleeding-safety","display_name":"bleeding safety","score":0.5600000023841858},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.7870000004768372}],"concepts":[{"id":"https://openalex.org/C2780638905","wikidata":"https://www.wikidata.org/wiki/Q414462","display_name":"Apixaban","level":5,"score":0.9533083438873291},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8486629724502563},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7538531422615051},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.7161399126052856},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.637408435344696},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5629405975341797},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5255146026611328},{"id":"https://openalex.org/C139254425","wikidata":"https://www.wikidata.org/wiki/Q1332167","display_name":"Volume of distribution","level":3,"score":0.49031737446784973},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.44916895031929016},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.38792741298675537},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.33349645137786865},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.32305946946144104},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2848634719848633},{"id":"https://openalex.org/C2778661090","wikidata":"https://www.wikidata.org/wiki/Q420262","display_name":"Rivaroxaban","level":4,"score":0.24916130304336548},{"id":"https://openalex.org/C2776301958","wikidata":"https://www.wikidata.org/wiki/Q407431","display_name":"Warfarin","level":3,"score":0.19448864459991455},{"id":"https://openalex.org/C2779161974","wikidata":"https://www.wikidata.org/wiki/Q815819","display_name":"Atrial fibrillation","level":2,"score":0.0536322295665741},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011517","descriptor_name":"Prothrombin Time","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D014018","descriptor_name":"Tissue Distribution","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019934","descriptor_name":"International Normalized Ratio","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061605","descriptor_name":"Administration, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065427","descriptor_name":"Factor Xa Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D065427","descriptor_name":"Factor Xa Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D065427","descriptor_name":"Factor Xa Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/cpdd.990","doi":"https://doi.org/10.1002/cpdd.990","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cpdd.990","pdf_url":null,"source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},{"id":"pmid:34342172","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/34342172","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology in drug development","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":35,"referenced_works":["https://openalex.org/W1507763452","https://openalex.org/W1558500336","https://openalex.org/W1568662837","https://openalex.org/W1748334772","https://openalex.org/W1913544684","https://openalex.org/W1976934051","https://openalex.org/W2014822095","https://openalex.org/W2026517280","https://openalex.org/W2032692864","https://openalex.org/W2038203531","https://openalex.org/W2038316072","https://openalex.org/W2055619480","https://openalex.org/W2073493628","https://openalex.org/W2073510057","https://openalex.org/W2073584640","https://openalex.org/W2082987265","https://openalex.org/W2103196751","https://openalex.org/W2114189419","https://openalex.org/W2116005824","https://openalex.org/W2116532362","https://openalex.org/W2119622751","https://openalex.org/W2120414434","https://openalex.org/W2120879113","https://openalex.org/W2128563057","https://openalex.org/W2131569638","https://openalex.org/W2133686162","https://openalex.org/W2139785591","https://openalex.org/W2149388786","https://openalex.org/W2162373453","https://openalex.org/W2162508946","https://openalex.org/W2166402206","https://openalex.org/W2167399732","https://openalex.org/W2203036336","https://openalex.org/W2237496421","https://openalex.org/W2617973506"],"related_works":["https://openalex.org/W1993406555","https://openalex.org/W2946652117","https://openalex.org/W1568662837","https://openalex.org/W2073584640","https://openalex.org/W2032692864","https://openalex.org/W1507763452","https://openalex.org/W2580470571","https://openalex.org/W2897274926","https://openalex.org/W2027008828","https://openalex.org/W4322758675"],"abstract_inverted_index":{"Abstract":[0],"This":[1],"randomized,":[2],"double\u2010blind,":[3],"placebo\u2010controlled,":[4],"ascending":[5],"single":[6,158],"intravenous":[7],"(IV)":[8],"bolus\u2010dose":[9],"study":[10],"evaluated":[11],"safety,":[12],"tolerability,":[13],"pharmacokinetics":[14],"(PK),":[15],"and":[16,47,69,79,97,111,129,136,163,181],"pharmacodynamics":[17],"(PD)":[18],"of":[19,58,95],"apixaban,":[20],"a":[21,167,186],"direct":[22],"factor":[23],"Xa":[24],"(FXa)":[25],"inhibitor":[26],"approved":[27],"for":[28,67,133],"multiple":[29],"indications.":[30],"Eight":[31],"healthy":[32],"subjects":[33],"were":[34,65,121,148,196],"randomized":[35],"3:1":[36],"(apixaban:placebo)":[37],"within":[38,143],"each":[39],"IV":[40,52,159],"dose":[41,169,188],"cohort":[42],"(0.5,":[43],"1.25,":[44],"2.5,":[45],"3.75,":[46],"5":[48,56],"mg).":[49],"The":[50],"2.5\u2010mg":[51],"panel":[53],"also":[54],"received":[55],"mg":[57],"oral":[59,85,177],"apixaban":[60,116,157],"or":[61,151],"placebo.":[62],"Blood":[63],"samples":[64],"collected":[66],"PK":[68],"PD,":[70],"including":[71],"international":[72],"normalized":[73,140],"ratio,":[74],"modified":[75],"prothrombin":[76],"time":[77],"(mPT),":[78],"anti\u2010FXa":[80,134],"activity.":[81],"Apixaban":[82,174,194],"had":[83,175],"66.2%":[84],"bioavailability,":[86,178],"dose\u2010proportional":[87,179],"exposure,":[88,180],"17":[89],"to":[90,99],"26":[91],"L":[92],"steady\u2010state":[93],"volume":[94],"distribution,":[96],"3.2":[98],"3.5":[100],"L/h":[101],"total":[102],"plasma":[103,117,183],"clearance.":[104,193],"Renal":[105],"clearance":[106,184],"was":[107,161],"\u224827%.":[108],"Anti\u2010FXa":[109],"activity":[110,135],"mPT":[112],"changes":[113],"followed":[114],"the":[115],"concentration\u2013time":[118],"profile;":[119],"both":[120],"highly":[122],"correlated":[123],"with":[124,190,198],"concentration":[125],"(R2":[126],"=":[127,131],"0.99":[128],"R2":[130],"0.93":[132],"mPT,":[137],"respectively).":[138],"International":[139],"ratio":[141],"remained":[142],"reference":[144],"range":[145,170],"(0.9\u20101.3).":[146],"There":[147],"no":[149],"serious":[150],"bleeding\u2010related":[152],"adverse":[153],"events.":[154],"Overall,":[155],"an":[156],"bolus":[160],"safe":[162],"well":[164],"tolerated":[165],"over":[166,185],"10\u2010fold":[168],"by":[171],"these":[172],"subjects.":[173],"good":[176],"constant":[182],"broad":[187],"range,":[189],"modest":[191],"renal":[192],"PD":[195],"consistent":[197],"reversible":[199],"FXa":[200],"inhibition.":[201]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2021-08-16T00:00:00"}